Curated News
By: NewsRamp Editorial Staff
July 22, 2026

Kairos Pharma and Bayer Partner to Target Prostate Cancer Resistance

Discuss on LinkedIn Discuss on Substack Discuss on Telegram
Original Source

TLDR

  • Kairos Pharma's ENV-105 collaboration with Bayer could enhance XOFIGO efficacy, offering a potential advantage in prostate cancer treatment.
  • ENV-105 inhibits CD105 signaling to overcome resistance, combined with XOFIGO's alpha radiation to target bone metastases in prostate cancer.
  • This collaboration aims to improve outcomes for advanced prostate cancer patients by providing a more durable and effective treatment option.
  • ENV-105 re-sensitizes tumors to radiation, showing over 13 months median progression-free survival in prostate cancer patients.

Impact - Why it Matters

This collaboration matters because it addresses a critical challenge in prostate cancer treatment: drug resistance. By combining ENV-105, which targets CD105 to overcome resistance, with XOFIGO, an FDA-approved radiopharmaceutical, the partnership could lead to more durable and effective therapies for patients with metastatic castration-resistant prostate cancer. For investors, it highlights Kairos Pharma's innovative approach and potential for significant clinical impact, while for patients, it offers hope for extended survival and improved quality of life.

Summary

Kairos Pharma (NYSE American: KAPA) has announced a strategic collaboration with Bayer to evaluate its lead antibody candidate, ENV-105 (carotuximab), in combination with Bayer’s XOFIGO(R) (radium-223 dichloride) for treating metastatic castration-resistant prostate cancer involving bone. ENV-105 is a first-in-class CD105/BMP signaling inhibitor designed to overcome cancer drug resistance and is currently in Phase 1 and Phase 2 clinical trials. Interim Phase 2 data previously reported by the company showed median progression-free survival exceeding 13 months in prostate cancer patients. XOFIGO is the only FDA-approved alpha-emitting radiopharmaceutical for symptomatic bone metastases in this patient population.

The collaboration aims to determine whether ENV-105 can enhance and extend responses to XOFIGO by targeting CD105, a protein linked to treatment resistance following androgen receptor inhibition and radiation therapy. Preclinical studies demonstrated ENV-105’s ability to re-sensitize tumors to radiation, and management believes the combination could offer a more durable treatment option for advanced prostate cancer patients. Based in Los Angeles, Kairos Pharma focuses on oncology therapeutics, leveraging structural biology to combat drug resistance and immune suppression. Its lead candidate, ENV-105, targets CD105 to reverse resistance and restore standard therapy effectiveness across multiple cancers. Currently, ENV-105 is in a Phase 2 trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer. ENV-105 has not yet been approved by the FDA or other regulators.

This news was disseminated by TinyGems, a specialized communications platform for small-cap and mid-cap companies, which is part of the Dynamic Brand Portfolio at IBN. TinyGems provides services like press release distribution via InvestorWire, editorial syndication to 5,000+ outlets, and social media distribution. For more details, visit the full press release at https://ibn.fm/emSc4.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Kairos Pharma and Bayer Partner to Target Prostate Cancer Resistance

blockchain registration record for this content.